Park Min, Kim Jeong Mi, Kim Hyo Joon
Department of Neurosurgery, Presbyterian Medical Center, Jeonju, Korea.
Korean J Neurotrauma. 2015 Oct;11(2):131-4. doi: 10.13004/kjnt.2015.11.2.131. Epub 2015 Oct 31.
In most cases, the postoperative course of a chronic subdural hematoma (CSDH) is good, but CSDHs sometimes remain after the inserted catheter is removed, and the outcomes of such remnant hematomas are unclear. As oral streptokinase-streptodornase (OSS) has anti-inflammatory and hematologic effects, we assessed the effects of OSS on remnant CSDHs through a retrospective analysis of clinical data.
This study included 101 patients with traumatic CSDH who had remnant CSDH after burr-hole trephination with the closed drainage system between October 2009 and December 2012. We assessed the clinical outcomes, remnant CSDH volume, and recurrence rate from computed tomography scans in order to evaluate the effects of OSS.
No significant differences were found in the changes in remnant hematoma volume between the OSS-treated and non-treated groups (p=0.531). The reoperation rate because of was 5.4% (2 patients) in the OSS-treated group and 6.3% (4 patients) in the non-treated group. The number of patients requiring reoperation did not differ between the groups (p=0.658).
OSS treatment was not associated with a significant reduction in the remnant CSDH volume or recurrence rate after burr-hole drainage. Thus, there seems to be no basis for using OSS in CSDH patients.
在大多数情况下,慢性硬膜下血肿(CSDH)的术后病程良好,但有时在拔除插入的导管后CSDH仍会残留,且此类残留血肿的转归尚不清楚。由于口服链激酶 - 链道酶(OSS)具有抗炎和血液学作用,我们通过对临床数据的回顾性分析评估了OSS对残留CSDH的影响。
本研究纳入了2009年10月至2012年12月期间101例创伤性CSDH患者,这些患者在采用闭合引流系统进行钻孔引流术后有残留CSDH。我们通过计算机断层扫描评估临床结局、残留CSDH体积和复发率,以评估OSS的效果。
OSS治疗组和未治疗组之间残留血肿体积的变化无显著差异(p = 0.531)。OSS治疗组因残留血肿进行再次手术的比例为5.4%(2例患者),未治疗组为6.3%(4例患者)。两组间需要再次手术的患者数量无差异(p = 0.658)。
OSS治疗与钻孔引流术后残留CSDH体积的显著减少或复发率降低无关。因此,在CSDH患者中使用OSS似乎没有依据。